ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN was reported 344 times

These side effects are most commonly reported by patients taking ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN:

# Side effect Count
0 OFF LABEL USE 33
1 HYPERAMMONAEMIA 31
2 FEBRILE NEUTROPENIA 28
3 NAUSEA 26
4 HYPERSENSITIVITY 21
5 PANCREATITIS 20
6 URTICARIA 19
7 RASH 18
8 VOMITING 17
9 NEUTROPENIA 15
10 ANAPHYLACTIC REACTION 14
11 AMMONIA INCREASED 12
12 HERPES SIMPLEX 11
13 SYSTEMIC CANDIDA 11
14 CEREBRAL CANDIDIASIS 10
15 RESPIRATORY MONILIASIS 10
16 SKIN CANDIDA 10
17 PYREXIA 9
18 STOMATOCOCCAL INFECTION 9
19 DRUG HYPERSENSITIVITY 7
20 ESCHERICHIA BACTERAEMIA 7
21 FATIGUE 7
22 DEATH 6
23 DECREASED APPETITE 6
24 HAEMORRHAGE 6
25 HEADACHE 6
26 SEPSIS 6
27 THROMBOCYTOPENIA 6
28 HYPOGLYCAEMIA 5
29 PAIN IN EXTREMITY 5
30 DIARRHOEA 4
31 DRUG LEVEL BELOW THERAPEUTIC 4
32 FLUSHING 4
33 INJECTION SITE PAIN 4
34 PANCREATITIS NECROTISING 4
35 SUPERIOR SAGITTAL SINUS THROMBOSIS 4
36 THERAPEUTIC PRODUCT EFFECT DECREASED 4
37 ANAEMIA 3
38 BACTERAEMIA 3
39 BACTERIAL INFECTION 3
40 BLOOD TRIGLYCERIDES INCREASED 3
41 CARDIAC ARREST 3
42 CONFUSIONAL STATE 3
43 COUGH 3
44 DEHYDRATION 3
45 DISSEMINATED INTRAVASCULAR COAGULATION 3
46 DRUG INEFFECTIVE 3
47 DRUG INTOLERANCE 3
48 DYSPNOEA 3
49 HYPERAMMONAEMIC ENCEPHALOPATHY 3
50 HYPERTRIGLYCERIDAEMIA 3
51 INFECTION 3
52 LYMPHADENOPATHY 3
53 MUCOSAL INFLAMMATION 3
54 MULTIPLE ORGAN DYSFUNCTION SYNDROME 3
55 NECROTISING FASCIITIS 3
56 PANCYTOPENIA 3
57 PLATELET COUNT DECREASED 3
58 PNEUMONIA 3
59 PRODUCT DOSE OMISSION ISSUE 3
60 PRURITUS 3
61 RASH ERYTHEMATOUS 3
62 RESPIRATORY FAILURE 3
63 SECONDARY IMMUNODEFICIENCY 3
64 SEIZURE 3
65 THERAPEUTIC PRODUCT EFFECT INCREASED 3
66 VIRAL INFECTION 3
67 VISION BLURRED 3
68 ABDOMINAL PAIN 2
69 ACUTE KIDNEY INJURY 2
70 AGITATION 2
71 ALANINE AMINOTRANSFERASE INCREASED 2
72 AMMONIA ABNORMAL 2
73 ARTHRALGIA 2
74 ASTHENIA 2
75 BASAL GANGLIA HAEMATOMA 2
76 BLOOD CULTURE POSITIVE 2
77 BRONCHOPULMONARY ASPERGILLOSIS 2
78 BURNING SENSATION 2
79 CANDIDA INFECTION 2
80 CARDIAC FAILURE 2
81 CEREBROVASCULAR ACCIDENT 2
82 CHEMOTHERAPEUTIC DRUG LEVEL BELOW THERAPEUTIC 2
83 CORONAVIRUS INFECTION 2
84 CULTURE WOUND POSITIVE 2
85 DISEASE PROGRESSION 2
86 ENCEPHALOPATHY 2
87 ENTEROBACTER TEST POSITIVE 2
88 ENTEROCOLITIS 2
89 ERYTHEMA 2
90 ESCHERICHIA TEST POSITIVE 2
91 EYE HAEMORRHAGE 2
92 EYE INFECTION FUNGAL 2
93 FACE OEDEMA 2
94 GROIN PAIN 2
95 HAEMATEMESIS 2
96 HAEMORRHAGIC STROKE 2
97 HOSPITALISATION 2
98 HYPERGLYCAEMIA 2
99 HYPERHIDROSIS 2
100 HYPERINSULINISM 2
101 HYPERTENSION 2
102 ILLNESS 2
103 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 2
104 INCORRECT DOSE ADMINISTERED 2
105 INFUSION RELATED REACTION 2
106 INJECTION SITE REACTION 2
107 LIPASE INCREASED 2
108 MENTAL STATUS CHANGES 2
109 MYALGIA 2
110 OPTIC NERVE SHEATH HAEMORRHAGE 2
111 PAIN 2
112 PARAINFLUENZA VIRUS INFECTION 2
113 PRODUCT PACKAGING QUANTITY ISSUE 2
114 PRODUCT QUALITY ISSUE 2
115 PRODUCT STORAGE ERROR 2
116 PSEUDOMONAL SEPSIS 2
117 RETINAL HAEMORRHAGE 2
118 RHINOVIRUS INFECTION 2
119 SEPTIC SHOCK 2
120 STOMATITIS 2
121 SYNCOPE 2
122 TOXICITY TO VARIOUS AGENTS 2
123 TREATMENT DELAYED 2
124 UNDERDOSE 2
125 UNEVALUABLE EVENT 2
126 VENOOCCLUSIVE LIVER DISEASE 2
127 VITREOUS FLOATERS 2
128 ABDOMINAL DISCOMFORT 1
129 ABDOMINAL PAIN UPPER 1
130 ABSCESS BACTERIAL 1
131 ACIDOSIS 1
132 ADMINISTRATION SITE REACTION 1
133 ADMINISTRATION SITE SWELLING 1
134 ALTERED STATE OF CONSCIOUSNESS 1
135 AMYLASE INCREASED 1
136 ANISOCORIA 1
137 ANTIBODY TEST POSITIVE 1
138 ANTITHROMBIN III DEFICIENCY 1
139 ASPARTATE AMINOTRANSFERASE INCREASED 1
140 ASPERGILLUS INFECTION 1
141 ASPERGILLUS TEST 1
142 BACK PAIN 1
143 BLOOD BICARBONATE DECREASED 1
144 BLOOD BILIRUBIN INCREASED 1
145 BLOOD CREATINE PHOSPHOKINASE INCREASED 1
146 BLOOD GLUCOSE INCREASED 1
147 BLOOD PRESSURE INCREASED 1
148 BONE PAIN 1
149 BRAIN DEATH 1
150 CARDIAC FAILURE ACUTE 1
151 CELLULITIS 1
152 CEREBRAL ASPERGILLOSIS 1
153 CEREBRAL DISORDER 1
154 CEREBRAL INFARCTION 1
155 CEREBRAL MASS EFFECT 1
156 CEREBRAL THROMBOSIS 1
157 CEREBRAL VENOUS SINUS THROMBOSIS 1
158 CHEMOTHERAPEUTIC DRUG LEVEL DECREASED 1
159 CHEST PAIN 1
160 CLOSTRIDIUM DIFFICILE COLITIS 1
161 CONDITION AGGRAVATED 1
162 CONSTIPATION 1
163 CONTUSION 1
164 COVID-19 1
165 CYSTITIS BACTERIAL 1
166 CYTOMEGALOVIRUS CHORIORETINITIS 1
167 CYTOMEGALOVIRUS VIRAEMIA 1
168 CYTOPENIA 1
169 DIFFUSE ALVEOLAR DAMAGE 1
170 DIZZINESS 1
171 DRUG CLEARANCE INCREASED 1
172 DRUG RESISTANCE 1
173 DYSKINESIA 1
174 EATING DISORDER 1
175 ELECTROCARDIOGRAM QT PROLONGED 1
176 ENTERITIS 1
177 ENTEROBACTER INFECTION 1
178 ENTEROCOCCAL INFECTION 1
179 ENTEROVIRUS INFECTION 1
180 ENZYME ACTIVITY DECREASED 1
181 ENZYME INHIBITION 1
182 ERYTHEMA NODOSUM 1
183 ESCHERICHIA INFECTION 1
184 EYE PAIN 1
185 FULL BLOOD COUNT DECREASED 1
186 FUNGAL INFECTION 1
187 GAIT DISTURBANCE 1
188 GEMELLA BACTERAEMIA 1
189 GENERAL PHYSICAL CONDITION ABNORMAL 1
190 GENERALISED TONIC-CLONIC SEIZURE 1
191 HAEMOGLOBIN DECREASED 1
192 HAEMORRHAGE INTRACRANIAL 1
193 HALLUCINATION 1
194 HEPATIC ENZYME INCREASED 1
195 HEPATIC FAILURE 1
196 HEPATIC FUNCTION ABNORMAL 1
197 HEPATIC STEATOSIS 1
198 HEPATOBILIARY DISEASE 1
199 HUMAN BOCAVIRUS INFECTION 1
200 HUMAN HERPESVIRUS 6 INFECTION 1
201 HYPERVOLAEMIA 1
202 HYPOFIBRINOGENAEMIA 1
203 HYPOPHAGIA 1
204 HYPOTENSION 1
205 ILEUS 1
206 IMMEDIATE POST-INJECTION REACTION 1
207 IMMUNE SYSTEM DISORDER 1
208 INADEQUATE DIET 1
209 INCORRECT PRODUCT ADMINISTRATION DURATION 1
210 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 1
211 INFARCTION 1
212 INFLAMMATION 1
213 INJECTION SITE CELLULITIS 1
214 INJECTION SITE ERYTHEMA 1
215 INJECTION SITE HYPERSENSITIVITY 1
216 INJECTION SITE INFLAMMATION 1
217 INJECTION SITE MASS 1
218 INJECTION SITE RASH 1
219 INTERCEPTED MEDICATION ERROR 1
220 INTERCEPTED PRODUCT PREPARATION ERROR 1
221 INTRACARDIAC THROMBUS 1
222 LETHARGY 1
223 LEUKAEMIA 1
224 LEUKOENCEPHALOPATHY 1
225 LIP SWELLING 1
226 LIVER FUNCTION TEST INCREASED 1
227 LOCALISED OEDEMA 1
228 LYMPHOID TISSUE HYPOPLASIA 1
229 MALAISE 1
230 MALIGNANT NEOPLASM PROGRESSION 1
231 MALNUTRITION 1
232 MANIA 1
233 MEDICATION ERROR 1
234 MINIMAL RESIDUAL DISEASE 1
235 MOBILITY DECREASED 1
236 MUSCULAR WEAKNESS 1
237 MUSCULOSKELETAL PAIN 1
238 MYCOBACTERIUM CHELONAE INFECTION 1
239 MYOSITIS 1
240 NECK PAIN 1
241 NEUROPATHY PERIPHERAL 1
242 NEUTROPHIL COUNT DECREASED 1
243 NOROVIRUS TEST POSITIVE 1
244 OESOPHAGEAL CANDIDIASIS 1
245 ORAL HERPES 1
246 OXYGEN SATURATION DECREASED 1
247 PALLOR 1
248 PANCREATITIS ACUTE 1
249 PARTIAL SEIZURES 1
250 PENILE PAIN 1
251 PLATELET TRANSFUSION 1
252 PLEURAL EFFUSION 1
253 PNEUMATOSIS INTESTINALIS 1
254 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 1
255 PRODUCT ADMINISTRATION INTERRUPTED 1
256 PRODUCT CLOSURE ISSUE 1
257 PRODUCT COMMUNICATION ISSUE 1
258 PRODUCT CONTAINER ISSUE 1
259 PRODUCT PREPARATION ERROR 1
260 PRODUCT USE IN UNAPPROVED INDICATION 1
261 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 1
262 PULMONARY EMBOLISM 1
263 PULMONARY HAEMORRHAGE 1
264 RASH MORBILLIFORM 1
265 RASH PAPULAR 1
266 RESPIRATORY DISTRESS 1
267 RESPIRATORY RATE INCREASED 1
268 SEPSIS SYNDROME 1
269 SKIN BURNING SENSATION 1
270 SKIN WEEPING 1
271 SOMNOLENCE 1
272 STAPHYLOCOCCAL INFECTION 1
273 SUBCUTANEOUS ABSCESS 1
274 SUBDURAL HAEMORRHAGE 1
275 SUBGALEAL HAEMATOMA 1
276 T-CELL TYPE ACUTE LEUKAEMIA 1
277 TACHYCARDIA 1
278 THERAPY CESSATION 1
279 THYMUS HYPOPLASIA 1
280 TRANSFUSION 1
281 TREMOR 1
282 TYPE 1 DIABETES MELLITUS 1
283 URINARY RETENTION 1
284 VASOGENIC CEREBRAL OEDEMA 1
285 VENOOCCLUSIVE DISEASE 1
286 VIRAEMIA 1
287 WHEEZING 1
288 WHITE MATTER LESION 1
289 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1